Navigation Links
Healthcare-Acquired Infection: Devices, Pharmaceuticals, and Environmental Products
Date:9/26/2011

NEW YORK, Sept. 26, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Healthcare-Acquired Infection: Devices, Pharmaceuticals, and Environmental Products

http://www.reportlinker.com/p0619272/Healthcare-Acquired-Infection-Devices-Pharmaceuticals-and-Environmental-Products.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

REPORT HIGHLIGHTS

* The global market for healthcare-acquired infection treatments were $16 billion in year 2010. This market is estimated to be around $19 billion in the year 2011 and is forecasted to cross $30 billion by 2016 at a CAGR of 9.5% for five year period.

* Markets for infection control devices and products were $8.3 billion in the year 2010 and are expected to reach $10.3 billion by 2011. This market is forecasted to cross $18.3 billion by 2016 at a CAGR of 12%.

* The market for pharmaceutical treatments is expected to be around $4.5 billion. This market is expected to increase at a 5.8% compound annual growth rate (CAGR) to reach $6 billion by 2016.

INTRODUCTION

REASONS FOR DOING THE STUDY

The objective of this study is to provide an in-depth analysis and forecast of the selected areas of the global healthcare-acquired infection (HAI) market. HAI is sometimes used to mean hospital-acquired infections, but for purposes of this report, HAI includes hospitals, nursing homes, outpatient surgery centers, and dialysis centers. Another term for healthcare-acquired infections is nosocomial infections.

The focus of this report is on devices, pharmaceuticals, and therapies currently used or under development for treatment of viral, bacterial, or fungal infections.

The global market for HAI products is estimated at between $10 billion and $15 billion in 2010, depending on the products included in the study, with high single-digit growth through 2016. Although the U.S. holds between 45% and 50% of the market, the fastest-growing regions for HAI treatments are the Asia-Pacific, which includes China, and Brazil.

STUDY GOALS AND OBJECTIVES

Healthcare-acquired infections are viral, bacterial, or fungal infections that patients acquire after they are admitted to a healthcare facility. Patients can acquire these infections from routine care; surgery; or as a complication from the use of medical devices such as ventilators, catheters, and intravenous lines.

The Centers for Disease Control (CDC) estimates that 2 million HAIs occur annually in the U.S. This leads to 100,000 deaths and costs an additional $36 billion to $45 billion in direct medical costs annually.

This report is designed to investigate the global HAI market by treatment area and by treatment type, with supporting tables and figures to illustrate projected growth. The report will include the U.S., Europe, Japan, and other countries such as China.

This report offers forecasts of the markets for devices, pharmaceuticals, and therapies by treatment segment and treatment type from 2011 through 2016, including supporting analyses for projections.

This report is a valuable tool for anyone assessing the HAI market and attempting to devise a strategy to successfully compete in this market. It provides background on the structure of the HAI market and the chief challenges and opportunities it faces. It offers the information needed to understand the current market and to address the emerging one.

This is an invaluable tool for business planners; acquisition specialists; licensing strategists; product managers; market research analysts; investing consultants; and others interested in the HAI market, its products, its participants, and its future.

METHODOLOGIES AND INFORMATION SOURCES

Information for this report was obtained from various primary and secondary research sources, including industry analysts, annual reports, Securities and Exchange Commission (SEC) reports, the World Health Organization (WHO), the National Institutes of Health (NIH), American Hospital Association (AHA), Infectious Disease Society of America (IDSA), American Society of Heating, Refrigerating and Air Conditioning Engineers (ASHRAE), National Institute of Allergy and Infectious Diseases (NIAID), the National Hospital Discharge Survey (NHDS), government agencies outside the U.S, and journal articles. Secondary sources include literature searches, product literature, and press releases.

When precise information was unavailable, a consensus is made using reasonable assumptions and estimates based on historical data.

CHAPTER ONE: INTRODUCTION 1

REASONS FOR DOING THE STUDY 1

STUDY GOALS AND OBJECTIVES 1

METHODOLOGIES AND INFORMATION SOURCES 2

ANALYST CREDENTIALS 2

RELATED BCC REPORTS 2

BCC ONLINE SERVICES 3

DISCLAIMER 3

CHAPTER TWO: SUMMARY 4

SUMMARY (CONTINUED) 4

SUMMARY TABLE GLOBAL MARKET FOR HAI TREATMENTS,

THROUGH 2016 ($ MILLIONS) 5

SUMMARY FIGURE GLOBAL MARKET FOR HAI TREATMENTS BY

GEOGRAPHICAL AREA, 2010 AND 2016 (%) 6

CHAPTER THREE: OVERVIEW 7

TABLE 1 GLOBAL PREVALENCE OF HEALTHCARE-ACQUIRED

INFECTIONS (PER 100 PATIENTS) 7

TABLE 1 (CONTINUED) 8

IMPORTANCE OF HAND WASHING 8

MOST COMMON HEALTHCARE-ASSOCIATED INFECTIONS 9

TABLE 2 CAUSES AND TYPES OF HEALTHCARE-ACQUIRED

INFECTIONS 9

TABLE 2 (CONTINUED) 10

GRAM-POSITIVE BACTERIA 10

S AUREUS 11

Transmission Routes 11

MRSA 11

Rate of Infection 11

Transmission Routes 12

TYPES OF PNEUMONIA 13

Pseudomonas Aeruginosa 13

Hospital-Acquired Pneumonia 13

Klebsiella Pneumonia 13

CLOSTRIDIUM DIFFICILE 14

MYCOBACTERIUM TUBERCULOSIS 14

Scope of Infection 14

E COLI 15

UTI Treatment Options 15

GASTROENTERITIS-CAUSING BACTERIA 15

Treatment Options 16

VANCOMYCIN-RESISTANT ENTEROCOCCI 16

Types of VRE 16

LEGIONELLA BACTERIA 16

Treatment Options 17

GRAM-NEGATIVE BACTERIA 17

PSEUDOMONAS AERUGINOSA 17

ACINETOBACTER BAUMANNII 18

STENOTROPHOMONAS MALTOPHILIA 18

VIRAL INFECTIONS 19

VIRAL INFECTION RESEARCH 19

HEPATITIS B AND C 19

Scope of Infection 20

Treatment 20

HIV 20

Treatment 21

NOROVIRUS 21

INFLUENZA VIRUS 21

Influenzavirus A, B, C 21

Transmission 22

Symptoms 22

Treatment 22

RESPIRATORY SYNCYTIAL VIRUS 23

Treatment 23

FUNGAL INFECTIONS 23

ASPERGILLUS INFECTIONS 23

Treatment 24

YEAST INFECTIONS 24

Candida Infections 24

PREVENTING HAI 25

DETERMINING THE MODE OF TRANSMISSION 25

CDC RECOMMENDATIONS FOR PREVENTION 26

TABLE 3 CDC MEASURES FOR PREVENTION OF HEALTHCAREACQUIRED

INFECTIONS, 2007 26

TABLE 3 (CONTINUED) 27

ROLES OF HEALTHCARE INSTITUTIONS AND INFECTION

CONTROL INDIVIDUALS 27

TABLE 4 SELECTED RESPONSIBILITIES OF INFECTION CONTROL

TEAM MEMBERS 28

TABLE 4 (CONTINUED) 29

COMPONENTS OF A HAI SURVEILLANCE SYSTEM 30

TABLE 5 MAIN STEPS AND COMPONENTS IN DEVELOPING AN

EFFECTIVE INFECTION-CONTROL SURVEILLANCE SYSTEM 30

SUITABLE SURVEYS IN DEVELOPING COUNTRIES 30

HEALTHCARE INFECTION POINTS OF GENERATION 31

HOSPITALS 31

SURGICAL PROCEDURES 31

AMBULATORY SURGERY CENTERS IN THE US 31

Number of Procedures in ASCs 32

Infection Control in ASCs 32

DIALYSIS CENTERS 32

US Dialysis Centers 32

Transmission of VRE 33

Hepatitis Transmission in US Dialysis Centers 33

Hepatitis Transmission in Dialysis Centers Outside the

US 33

ASSISTED LIVING AND LONG-TERM CARE FACILITIES 34

TREATMENTS 34

PROACTIVE MEASURES 34

Environmental Controls 35

Device Design 35

REACTIVE MEASURES 35

CHANGES IN THE INDUSTRY 35

TABLE 6 SELECTED MERGERS AND/OR ACQUISITIONS, 2005–2011

($ MILLIONS) 36

CHAPTER FOUR: GLOBAL HEALTHCARE-ACQUIRED INFECTION

MARKET 37

US MARKET 37

US HEALTHCARE SPENDING 37

SCOPE OF HEALTHCARE-ACQUIRED INFECTIONS IN US 38

Ventilator-Associated Pneumonia 38

RATE OF INFECTION 39

Intensive Care Units 39

Surgical Site Infections 39

Fungal Infections 40

COSTS 40

US PREVENTION ACTION PLAN 41

TABLE 7 HHS ACTION PLAN FOR HAI PREVENTION (%

REDUCTION) 41

EUROPEAN MARKET 42

SCOPE 42

HELICS 42

RATE OF INFECTION AND COSTS 42

JAPANESE MARKET 43

SCOPE 43

RATE OF INFECTION 44

CHINESE MARKET 45

SCOPE 45

RATE OF INFECTION 45

REST OF THE WORLD MARKET 45

SCOPE 46

RATE OF INFECTION 46

Rate of Infection (Continued) 47

OPPORTUNITIES AND CHALLENGES FOR HAI INDUSTRY 48

MEDICAL DEVICE OPPORTUNITIES AND CHALLENGES 48

Challenges 48

ENVIRONMENTAL AND STRUCTURAL OPPORTUNITIES

AND CHALLENGES 49

Challenges 49

NEW TREATMENTS 49

PHARMACEUTICAL MARKET OPPORTUNITIES AND

CHALLENGES 49

Patent Expiry 50

TABLE 8 SELECTED HAI-RELATED PHARMACEUTICAL PATENT

EXPIRATIONS, 2005–2020 50

Pipeline Limitations 50

Global Recession 51

Regulatory Restrictions 51

Generic Competition 51

IMPACT OF DEMOGRAPHIC CHANGES 52

DEMOGRAPHIC CHANGES IN THE US 52

DEMOGRAPHIC CHANGES OUTSIDE THE US 52

Demographic Changes Outside the US (Continued) 53

CHAPTER FIVE: HAI PHARMACEUTICAL MARKET 54

GLOBAL MARKETS 54

ROLE OF EMERGING NATIONS 54

PHARMACEUTICALS USED FOR HEALTHCARE-ACQUIRED

INFECTIONS 55

TABLE 9 GLOBAL MARKET FOR HAI PHARMACEUTICALS BY TYPE,

THROUGH 2016 ($ MILLIONS) 55

GLOBAL GROWTH RATES FOR PHARMACEUTICALS 55

TABLE 10 ESTIMATED GROWTH OF PHARMACEUTICAL

HEALTHCARE SPENDING BY REGION, THROUGH 2016 (%) 56

VIRAL HAI PHARMACEUTICALS 56

TABLE 11 SELECTED VIRAL HAI PHARMACEUTICALS BY NAME,

INDICATION, AND MANUFACTURER, 2010 57

FIGURE 1 ESTIMATED GLOBAL MARKET SHARE FOR

PRESCRIPTION PHARMACEUTICALS TO TREAT VIRAL HAI BY

COMPANY, 2010 (%) 58

FIGURE 2 GLOBAL MARKET FOR VIRAL BY DISEASE TYPE(%) 59

VIRAL PHARMACEUTICAL MARKET BY CONDITION 59

TABLE 12 GLOBAL MARKET FOR PHARMACEUTICALS TO TREAT

VIRAL HAI BY CONDITION, THROUGH 2016 ($ MILLIONS) 60

BACTERIAL HAI PHARMACEUTICALS 60

TABLE 13 SELECTED BACTERIAL HAI PHARMACEUTICALS BY

NAME, INDICATION, AND MANUFACTURER, 2010 60

TABLE 13 (CONTINUED) 61

DRUG CLASSES 61

Aminoglycosides 62

B-Lactam Antibiotics 62

Cephalosporins 62

Glycopeptides 63

Lincosamides 63

Lipopeptides 63

Carbapenems 63

Penicillins 64

Polypeptides 64

Macrolides 65

Quinolones 65

Tetracyclines 65

Tuberculosis 65

Sulfonamides 65

Other Formulations 65

FIGURE 3 GLOBAL MARKET SHARE FOR PRESCRIPTION

PHARMACEUTICALS TO TREAT BACTERIAL HAI BY COMPANY,

2010 (%) 66

TABLE 14 GLOBAL MARKET FOR PHARMACEUTICALS TO TREAT

BACTERIAL HAI, THROUGH 2016 ($ MILLIONS) 67

TABLE 15 GLOBAL MARKET FOR PHARMACEUTICALS TO TREAT

BACTERIAL HAI BY CONDITION, THROUGH 2016 ($ MILLIONS) 68

FUNGAL HAI PHARMACEUTICALS 68

TABLE 16 SELECT LISTING OF PHARMACEUTICALS TO TREAT

FUNGAL INFECTIONS BY NAME, TYPE, AND MANUFACTURER,

2010 68

TABLE 17 GLOBAL MARKET FOR PHARMACEUTICALS TO TREAT

FUNGAL HAI, THROUGH 2016 ($ MILLIONS) 69

FIGURE 4 MARKET FOR PHARMACEUTICALS TO TREAT FUNGAL

HAI BY COMPANY, 2010 (%) 70

GLOBAL OPPORTUNITIES 70

CHAPTER SIX: HAI ENVIRONMENTAL TREATMENT MARKET 71

GLOBAL HAI ENVIRONMENTAL TREATMENT MARKET 71

TABLE 18 GLOBAL MARKET FOR ENVIRONMENTAL PRODUCTS

DESIGNED TO MINIMIZE HEALTHCARE-ACQUIRED

INFECTIONS, THROUGH 2016 ($ MILLIONS) 71

PLANNING FOR CONSTRUCTION OR RENOVATION: US 72

Plans Involving Infection Control 72

AIR TREATMENT 72

ROOM FILTRATION SYSTEMS 73

ROOM PRESSURIZATION 74

HYDROGEN PEROXIDE VAPOR 74

Dedicated Airborne Isolation Rooms 75

WATER TREATMENT 75

DESIGN OF SINKS AND OTHER WATER FACILITIES 75

CLEANING PHYSICAL SURFACES 75

DISINFECTION 76

Advantages and Disadvantages of Disinfectants 76

TABLE 19 ADVANTAGES AND DISADVANTAGES OF COMMONLY

USED DISINFECTANTS 77

TABLE 19 (CONTINUED) 78

PHENOLICS 78

OXIDIZING AGENTS 78

HALOGENS 79

ALDEHYDES 79

QUATERNARY AMINES 79

ALCOHOLS 80

TABLE 20 GLOBAL MARKET FOR DISINFECTANT PRODUCTS

DESIGNED TO MINIMIZE HEALTHCARE-ACQUIRED

INFECTIONS, THROUGH 2016 ($ MILLIONS) 80

FIGURE 5 GLOBAL MARKET FOR DISINFECTANT PRODUCTS BY

TYPE, 2010 (%) 80

FIGURE 5 (CONTINUED) 81

PATIENT SKIN PREPARATION DISINFECTANTS 81

IODINE 81

POVIDONE-IODINE SOLUTIONS 82

CHLORHEXIDINE GLUCONATE 82

TABLE 21 GLOBAL MARKET FOR PATIENT PREPARATION

DISINFECTANTS, THROUGH 2016 ($ MILLIONS) 82

STERILIZATION SYSTEMS FOR INFECTION CONTROL 83

TABLE 22 GLOBAL MARKET FOR STERILIZATION DESIGNED TO

MINIMIZE HEALTHCARE-ACQUIRED INFECTIONS, THROUGH

2016 ($ MILLIONS) 83

CHEMICAL STERILIZATION 84

ETO Sterilization 84

Major Players in Chemical Sterilization 85

OTHER CHEMICAL STERILIZATION 85

Peracetic Acid 85

Hydrogen Peroxide 85

Chlorine Dioxide 86

Ozone 86

STEAM STERILIZATION 86

TABLE 23 SELECTED PLASTIC MATERIALS THAT RESPOND WELL

TO STEAM STERILIZATION 87

Autoclaving 87

Major Players in Heat Sterilization 88

CHAPTER SEVEN: HAI MEDICAL DEVICES: CATHETERS, PATIENT

VENTILATION SYSTEMS, AND IN-LINE STERILIZATION FILTERS 89

SELECTED GLOBAL MEDICAL HAI DEVICE MARKET 89

TABLE 24 GLOBAL MARKET FOR MEDICAL DEVICES THAT

MINIMIZE HEALTHCARE-ACQUIRED INFECTIONS, THROUGH

2016 ($ MILLIONS) 90

CATHETERS 90

USE OF COATINGS 91

CATHETER COATINGS 91

TABLE 25 SELECTED CATHETER PRODUCTS WITH ANTIBIOTIC

PROPERTIES 91

Silver Coating 92

SURFACE-MODIFIED CATHETER 92

TABLE 26 GLOBAL MARKET FOR CATHETERS WITH

ANTIMICROBIAL PROPERTIES, THROUGH 2016 ($ MILLIONS) 93

FIGURE 6 HAI CATHETER MARKET SHARES BY URINARY, CVC,

PICC, AND OTHER SEGMENTS, 2011 AND 2016 (%) 93

FIGURE 6 (CONTINUED) 94

URINARY TRACT CATHETERS 94

CENTRAL VENOUS CATHETERS 94

Dialysis Catheters 95

Catheter-Related Bloodstream Infections 95

Catheter-Related Bloodstream Infections

(Continued) 96

TABLE 27 POTENTIAL SOURCES OF CRBSI 97

PERIPHERALLY INSERTED CENTRAL VENOUS

CATHETERS 97

MARKET OPPORTUNITIES FOR CATHETER

MANUFACTURERS 97

CATHETER GROWTH IN REGIONAL MARKETS 98

TABLE 28 GLOBAL HAI CATHETER MARKET BY REGION,

THROUGH 2016 ($ MILLIONS) 98

FIGURE 7 GLOBAL HAI CATHETER MARKET BY REGION, 2011 AND

2016 (%) 99

PATIENT VENTILATION DEVICES 100

TABLE 29 GLOBAL MARKET FOR PATIENT VENTILATION

PRODUCTS, THROUGH 2016 ($ MILLIONS) 100

TYPES OF VENTILATION DEVICES 101

Non-Invasive Ventilators 101

TABLE 30 GLOBAL MARKET FOR NON-INVASIVE VENTILATIONS

SYSTEMS FOR USE WITH PATIENTS WHO HAVE HAIS,

THROUGH 2016 ($ MILLIONS) 102

ENDOTRACHEAL TUBES AND VENTILATION SYSTEMS 102

Coated Endotracheal Tubes 102

Tapered Endotracheal Tubes 103

TABLE 31 GLOBAL MARKET FOR COATED ENDOTRACHEAL TUBES

DESIGNED TO MINIMIZE VAP, THROUGH 2016 ($ MILLIONS) 103

IN-LINE STERILE IV FILTRATION 103

TABLE 32 GLOBAL STERILE IV FILTER MARKET, THROUGH 2016 ($

MILLIONS) 104

CHAPTER EIGHT: REGULATIONS AND PATENTS 105

US INFECTION CONTROL PROGRAMS 105

INFECTION CONTROL MEASURES AND PROTOCOLS 106

US REGULATIONS 106

HOSPITAL INFECTIONS DISCLOSURE ACT 106

CURRENT AND PENDING REQUIREMENTS 106

Affordable Care Act and Implications for the

Pharmaceutical Industry 107

Biosimilars 107

CMS Reimbursement for HAIs 108

EUROPEAN REGULATIONS 108

IMPLICATIONS FOR PHARMACEUTICAL

MANUFACTURERS 108

JAPANESE REGULATIONS 109

CHINESE REGULATIONS 110

PATENTS 110

PATENTS BY MANUFACTURER 110

TABLE 33 PATENTS BY MANUFACTURER, 2005–2011 111

TABLE 33 (CONTINUED) 112

TABLE 33 (CONTINUED) 113

PATENTS BY DATE OF ISSUE 113

TABLE 34 PHARMACEUTICAL PATENTS BY DATE OF ISSUE, 2005–

2011 114

TABLE 34 (CONTINUED) 115

PATENTS BY MANUFACTURER 115

TABLE 35 PATENTS BY MANUFACTURER 115

TABLE 35 (CONTINUED) 116

PATENTS FOR DELIVERY OF PHARMACEUTICALS 117

TABLE 36 PATENT BY INDICATION: PHARMACEUTICAL DELIVERY,

2005–2011 117

BACTERIAL PHARMACEUTICAL PATENTS 117

TABLE 37 PATENTS BY INDICATION: BACTERIAL

PHARMACEUTICAL, 2005–2011 118

TABLE 37 (CONTINUED) 119

TABLE 37 (CONTINUED) 120

TABLE 37 (CONTINUED) 121

FUNGAL PHARMACEUTICAL PATENTS 121

TABLE 38 PATENT BY INDICATION: FUNGAL PHARMACEUTICAL,

2010 121

VIRAL PHARMACEUTICAL PATENTS 122

TABLE 39 PATENTS BY INDICATION: VIRAL PHARMACEUTICAL,

2005–2011 122

TABLE 39 (CONTINUED) 123

TABLE 39 (CONTINUED) 124

ENVIRONMENTAL CONTROLS 125

TABLE 40 PATENT BY INDICATION: AIR FILTRATION, 2005–2011 125

TABLE 41 PATENTS BY INDICATION: WATER TREATMENT, 2005–

2011 126

PATENTS FOR SURFACE DISINFECTANTS 126

TABLE 42 PATENTS BY INDICATION: DISINFECTANT SURFACES,

2005–2011 127

TABLE 42 (CONTINUED) 128

TABLE 42 (CONTINUED) 129

TABLE 43 PATENT BY INDICATION: SOLID WASTE TREATMENT,

2005–2011 130

PATENTS FOR DIAGNOSTIC PROCESSES 130

TABLE 44 PATENTS BY INDICATION: DIAGNOSTIC, 2006–2011 131

TABLE 44 (CONTINUED) 132

MEDICAL DEVICES 132

TABLE 45 PATENTS BY INDICATION: CATHETER, 2008–2011 132

TABLE 45 (CONTINUED) 133

TABLE 45 (CONTINUED) 134

TABLE 45 (CONTINUED) 135

TABLE 46 PATENTS BY INDICATION: ANTIMICROBIAL COATINGS,

2005–2011 135

TABLE 46 (CONTINUED) 136

TABLE 46 (CONTINUED) 137

TABLE 46 (CONTINUED) 138

TABLE 46 (CONTINUED) 139

TABLE 46 (CONTINUED) 140

CHAPTER NINE: CURRENT RESEARCH AND EMERGING THERAPIES 141

EMERGING RESEARCH 141

RAPID TESTING 141

ANTISEPTIC WASHES 142

PHARMACEUTICALS 142

MERCK 142

Boceprivir 142

VERTEX 142

Teleprivir 142

TIBOTEC 143

CEREXA 143

Ceftaroline 143

NXL104 143

BASILEA PHARMACEUTICALS 143

Ceftobiprole 143

Delafloxacin 144

JOHNSON & JOHNSON 144

Doribax 144

CUBIST PHARMACEUTICALS 145

CSA-201 145

CXA183,315 145

TOYAMA CHEMICAL 145

T-705 145

T-3912 145

T-2307 146

GLAXOSMITHKLINE 146

OPTIMER PHARMACEUTICALS 146

Fidaxomicin 146

AURICX 146

BPH-652 146

PFIZER 147

THE MEDICINES COMPANY 147

Oritavancin 147

STERILIZATION AND DISINFECTION 147

SHARKLET TECHNOLOGIES 147

HEALTHCARE FACILITY DESIGN 148

MEDICAL DEVICE DESIGN 148

ONDINE BIOMEDICAL 148

CERAGENIX PHARMACEUTICALS, INC 148

RENAL SEPSIS MICROFILTER 149

CHAPTER TEN: COMPANY PROFILES 150

PHARMACEUTICALS 150

ABBOTT LABORATORIES 150

Business Overview 150

Financials 150

Products 150

ASTELLAS PHARMA, INC 151

Business Overview 151

Financial Information 151

Products 151

ASTRA TECH 152

ASTRAZENECA, PLC 152

Business Overview 152

Financials 152

Products 152

BACTIGUARD, AB 153

Business Overview 153

Financials 153

Products 153

BASILEA PHARMACEUTICA, LTD 153

Business Overview 154

Financials 154

Products 154

BAYER, AG (MILES-BAYER) 154

Business Overview 155

Financials 155

Products 155

BOEHRINGER INGELHEIM, GMBH 155

Business Overview 155

Financials 156

Products 156

BRISTOL-MYERS SQUIBB 156

Business Overview 156

Financials 156

Products 157

CEREXA, INC (FOREST LABORATORIES) 157

Business Overview 157

Financials 157

Products 157

CUBIST PHARMACEUTICALS 158

Business Overview 158

Financials 158

Products 158

ELAN CORPORATION 159

Business Overview 159

Financials 159

Products 160

FOREST LABORATORIES 160

Business Overview 160

Financials 160

Products 160

ELI LILLY AND COMPANY 161

Business Overview 161

Financials 161

Products 161

GILEAD SCIENCES 162

Business Overview 162

Financials 162

Products 162

GLAXOSMITHKLINE 162

Business Overview 162

Financials 163

Products 163

JOHNSON & JOHNSON 163

Business Overview 163

Financial Information 164

Products 164

MEDIMMUNE PHARMACEUTICALS 164

Business Overview 164

Financials 164

Products 165

MERCK 165

Business Overview 165

Financials 165

Products 165

NABI BIOPHARMACEUTICALS 166

Business Overview 166

Financials 166

Products 167

PFIZER 167

Business Overview 167

Financials 167

Products 168

ROCHE PHARMACEUTICALS 168

Business Overview 168

Financials 168

Products 169

SANOFI AVENTIS 169

Business Overview 169

Financials 169

Products 170

SCHERING-PLOUGH 170

THE MEDICINES COMPANY 170

Business Overview 170

Financials 170

Products 170

THERAVANCE 171

Business Overview 171

Financials 171

Products 171

TOYAMA CHEMICAL CO, LTD 172

Business Overview 172

Financials 172

Products 172

VERTEX PHARMACEUTICALS, INC 173

Business Overview 173

Financials 173

Products 173

VIROPHARMA, INC 173

Business Overview 174

Financials 174

Products 174

ENVIRONMENTAL PRODUCTS 174

3M HEALTHCARE, MEDICAL DIVISION 174

Business Overview 174

Financials 175

Products 175

ADVANCED STERILIZATION PRODUCTS 175

Business Overview 175

Financials 175

Products 176

ANDERSEN PRODUCTS, INC 176

Business Overview 176

Financials 176

Products 177

BAXTER INTERNATIONAL 177

Business Overview 177

Financials 177

Products 177

DIVERSEY, INC 178

Business Overview 178

Financials 178

Products 179

ECOLAB 179

Business Overview 179

Financials 179

Products 179

GETINGE USA, INC 180

Business Overview 180

Financials 180

Products 180

PRIMUS STERILIZER CO, INC 181

Business Overview 181

Financials 181

Products 181

RUHOF CORP 181

Business Overview 181

Financials 181

Products 182

STERIGENICS 182

Business Overview 182

Financials 182

Products 182

STERIS CORP 183

Business Overview 183

Financials 183

Products 183

TUTTANAUER USA CO, LTD 184

Business Overview 184

Financials 184

Products 184

ULTRAVIOLET DEVICES, INC 184

Business Overview 184

Financials 185

Products 185

XENEX HEALTHCARE SERVICES 185

Business Overview 185

Financials 185

Products 185

INFECTION CONTROL DEVICES 186

B BRAUN MELSUNGEN, AG 186

Business Overview 186

Financials 186

Products 186

BECTON DICKINSON 187

Business Overview 187

Financials 187

Products 187

BIOMÉRIEUX, INC 188

Business Overview 188

Financials 188

Products 189

CANTEL MEDICAL CORP 189

Business Overview 189

Financials 189

Products 189

CAREFUSION CORP 190

Business Overview 190

Financials 190

Products 191

CEPHEID 191

Business Overview 191

Financials 191

Products 191

CLOROX CO 192

Business Overview 192

Financials 192

Products 192

COLOPLAST GROUP 192

Business Overview 193

Financials 193

Products 193

CONVATEC 193

Business Overview 193

Financial 193

Products 194

COOK MEDICAL 194

Business Overview 194

Financials 194

Products 195

COVIDIEN, PLC 195

Business Overview 195

Financials 195

Products 195

CR BARD 196

Business Overview 196

Financials 196

Products 197

DRAGER MEDICAL, LTD, UK 197

Business Overview 197

Financials 197

Products 198

HOLLISTER, INC 198

Business Overview 198

Financials 198

Products 198

KIMBERLY-CLARK HEALTHCARE 198

Business Overview 198

Financials 199

Products 199

ODINE BIOMEDICAL, INC 199

Business Overview 199

Financials 200

Products 200

TELEFLEX MEDICAL 200

Business Overview 200

Financials 200

Products 201

WELCH ALLYN, INC 201

Business Overview 201

Financials 201

Products 201

To order this report:

Drug and Medication Industry: Healthcare-Acquired Infection: Devices, Pharmaceuticals, and Environmental Products

Drug and Medication Business News

More  Industry Analysis and Insights

Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved


Related medicine technology :

1. Current Concepts in Clostridium difficile Infection: A Focus on Recurrent Disease
2. RSB Spine, LLC, Announces Distribution Agreement with Paradigm BioDevices, Inc.
3. Circle Medical Devices, Texcel Medical Merge to Form CIRTEC Medical Systems
4. Binder Biomedical, Inc. Announces the Release of the X-GRAFT(TM) Interspinous Device, as Part of Their QUANTUM(TM) Line of Spinal Allograft Devices, Manufactured at the University of Miami Tissue Bank
5. RoundTable Healthcare Partners Portfolio Company, Argon Medical Devices, Inc., Acquires Critical Care and Extended Dwell Catheter Product Platforms From BD
6. Intelligent Medical Devices, Inc. (IMDx) Enters into an Agreement with Abbott for the Distribution of a Broad Menu of Molecular Tests
7. MRI Medical Inc. Changing Name to Xeridiem Medical Devices, Inc.
8. Molecular Devices, Inc. and ChanTest Corporation Sign Cell Line Distribution Agreement
9. Reportlinker Adds Global Market for Medical Devices, 2nd Edition
10. Reportlinker Adds Neurology Devices Market Outlook in United States to 2017 - Neurostimulation Devices, Interventional Neurology and Others
11. Reportlinker Adds Minimally Invasive Surgical Devices, World Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 Research and ... Global Market - Forecast to 2022" report to their ... treatment method for the patients with kidney failure, it replaces ... fluid from the patient,s blood and thus the treatment helps ... and chloride in balance. Increasing number of ...
(Date:6/23/2016)... June 23, 2016 Research and Markets ... Medical Market Analysis 2016 - Forecast to 2022" report ... The report contains up to date financial data derived from ... of major trends with potential impact on the market during ... market segmentation which comprises of sub markets, regional and country ...
(Date:6/23/2016)... and INDIANAPOLIS , June ... receiving a Lilly Diabetes Tomorrow,s Leaders Scholarship is any ... scholarship winners, announced today online at www.diabetesscholars.org ... type 1 diabetes stand in the way of academic ... supported the Foundation,s scholarship program since 2012, and continues ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... ... Conventional wisdom preaches the benefits of moderation, whether it’s a matter of ... too high can result in disappointment, perhaps even self-loathing. However, those who set the ... Research from PsychTests.com reveals that behind the tendency to set low expectations ...
(Date:6/24/2016)... ... , ... Marcy was in a crisis. Her son James, eight, was out of control. Prone ... physically. , “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If ... at my other children and say he was going to kill them. If we ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA is ... Road To Recovery® program to drive cancer patients to and from their cancer treatments. ... the highest quality of life and ongoing independence. Getting to and from medical ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Haute Beauty ... Barry M. Weintraub as a prominent plastic surgeon and the network’s newest partner. ... and the most handsome men, look naturally attractive. Plastic surgery should be invisible.” ...
(Date:6/24/2016)... ... June 24, 2016 , ... Venture Construction Group (VCG) ... held on June 20th at the Woodmont Country Club at 1201 Rockville Pike, Rockville, ... dedicated to helping service members that have been wounded in battle and their families. ...
Breaking Medicine News(10 mins):